Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

4.25
+0.27006.78%
Post-market: 4.250.00000.00%18:16 EDT
Volume:1.09M
Turnover:4.55M
Market Cap:512.53M
PE:-8.02
High:4.27
Open:4.10
Low:4.03
Close:3.98
52wk High:4.89
52wk Low:1.10
Shares:120.60M
Float Shares:116.53M
Volume Ratio:0.80
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5300
EPS(LYR):-0.5300
ROE:-50.20%
ROA:-24.32%
PB:4.97
PE(LYR):-8.02

Loading ...

Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum

TIPRANKS
·
Apr 17

Oppenheimer Initiates Aclaris Therapeutics at Outperform With $10 Price Target

MT Newswires Live
·
Apr 16

Aclaris Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $10

THOMSON REUTERS
·
Apr 16

Aclaris Therapeutics Initiated at Outperform by Oppenheimer

Dow Jones
·
Apr 16

U.S. RESEARCH ROUNDUP-CME Group, M&T Bank, PNC Financial Services

Reuters
·
Apr 16

Cardiff Oncology names Mani Mohindru CEO, appoints Josh Muntner CFO

Reuters
·
Apr 10

Aclaris CEO to join fireside chat at H.C. Wainwright skin disease conference

Reuters
·
Apr 08

Aclaris Therapeutics Price Target Maintained With a $8.00/Share by Wedbush

Dow Jones
·
Mar 31

Aclaris Therapeutics Phase 2a week 12 EASI improvement climbs 77% on ATI-2138 10 mg BID; BSA improvement grows 70%

Reuters
·
Mar 27

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

GlobeNewswire
·
Mar 27

Aclaris Therapeutics to present Phase 2a ATI-2138 atopic dermatitis trial results at 2026 AAD meeting

Reuters
·
Mar 20

Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 19

Aclaris Therapeutics completes enrollment of 109 patients in Phase 2 bosakitug trial for atopic dermatitis

Reuters
·
Mar 18

Aclaris Therapeutics Inc - Top Line Results From Phase 2 Trial Expected in Q4 2026

THOMSON REUTERS
·
Mar 18

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

GlobeNewswire
·
Mar 18

Aclaris Therapeutics Raises $20 Million in Equity Financing

TIPRANKS
·
Mar 12

Aclaris Therapeutics sells 5.7 million shares for USD 20 million

Reuters
·
Mar 12

Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference

GlobeNewswire
·
Mar 03

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 27

Craig-Hallum Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)

TIPRANKS
·
Feb 26